Literature DB >> 2004366

Estrogen and progesterone receptors in the normal female breast.

D Ricketts1, L Turnbull, G Ryall, R Bakhshi, N S Rawson, J C Gazet, C Nolan, R C Coombes.   

Abstract

We have studied estrogen receptor (ER) and progesterone receptor (PR) in normal breast by immunocytochemistry using tissue biopsies and fine needle aspirates (FNA) and, in the case of ER, by enzyme immunoassay. For ER we found a high degree of reproducibility for biopsies taken from the upper outer quadrant: FNA, r = 0.56 (P less than 0.002); tissue section immunocytochemistry, r = 0.89 (P less than 0.0001); and enzyme immunoassay, r = 0.76 (P less than 0.0001). For PR, FNA (r = 0.56, P less than 0.002) and tissue section (r = 0.97, P less than 0.0001) were also found to be reproducible techniques. Using enzyme immunoassay, we were able to measure ER accurately in normal breast tissue. In 59 samples we found a range of 0-37 fmol/mg cytosol protein (mean, 4 fmol/mg). In an age-matched group of 126 women with breast cancer, we found a significantly higher ER [range, 0-139 fmol/mg; mean, 37 fmol/mg (P less than 0.001)]. We then analyzed the ER and PR content of FNAs obtained from the upper outer quadrant of the normal breast in 143 normal women. We found that in only 23 of 143 samples (16%) were greater than or equal to 50% epithelial cells stained. There was a relationship between ER and PR (P = 0.03) and a higher ER content in European women than in non-European women (P less than 0.03). The PR content was related to high body mass index (P less than 0.02) and family history of breast cancer (P = 0.04). Samples tended to be more frequently ER positive by FNA if taken in the follicular phase of the menstrual cycle. We conclude that, although the levels of ER and PR are low in normal breast, they can be accurately measured. There is significant variation of ER and PR with several clinical parameters.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004366

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

Review 1.  Estrogen responsiveness and control of normal human breast proliferation.

Authors:  E Anderson; R B Clarke; A Howell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 2.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

Review 3.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

4.  Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines.

Authors:  Trevor A Petrel; Robert W Brueggemeier
Journal:  J Cell Biochem       Date:  2003-01-01       Impact factor: 4.429

5.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

Authors:  M Gugger; J C Reubi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

6.  Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk.

Authors:  Susan E Hankinson; A Heather Eliassen
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

7.  A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Authors:  Oukseub Lee; Katherine Page; David Ivancic; Irene Helenowski; Vamsi Parini; Megan E Sullivan; Julie A Margenthaler; Robert T Chatterton; Borko Jovanovic; Barbara K Dunn; Brandy M Heckman-Stoddard; Kathleen Foster; Miguel Muzzio; Julia Shklovskaya; Silvia Skripkauskas; Piotr Kulesza; David Green; Nora M Hansen; Kevin P Bethke; Jacqueline S Jeruss; Raymond Bergan; Seema A Khan
Journal:  Clin Cancer Res       Date:  2014-07-15       Impact factor: 12.531

8.  Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.

Authors:  D K Biswas; L Averboukh; S Sheng; K Martin; D S Ewaniuk; T F Jawde; F Wang; A B Pardee
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

Review 9.  Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.

Authors:  O W Petersen; L Rønnov-Jessen; V M Weaver; M J Bissell
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

10.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.